Friday, 05 March 2021 | 22:55 WIB

Production of Nusantara Vaccine Can Reach 10 Million Doses Per Month

Former Indonesian Health Minister and initiator of VaknusTerawan Agus Putranto (center) (special)

JAKARTA, NETRALNEWS.COM - The Nusantara Vaccine (Vaknus) has been in development since September of last year, and it has now reached the second phase of clinical testing. Nusantara Vaccine is a dendritic cell-based vaccine developed by AIVITA Biomedical Inc. in California, United States (US).

Former Indonesian Health Minister and initiator of VaknusTerawan Agus Putranto said the vaccine will be mass-produced if it has passed all clinical test phases and obtain permission from the Indonesian National Agency for Food and Drug Control (BPOM) and the Indonesian Ulema Council (MUI).

"It can be produced up to ten million doses per month," Terawan said in the written statement received in Jakarta on Tuesday (02/16/2021).

Terawan said Indonesia should be able to produce COVID-19 vaccine. "We need to have independent skills to produce vaccines in which the platform is individual," he said.

The Vaknus development involves researchers from Universitas Gadjah Mada in Yogyakarta, Universitas Sebelas Maret in Solo, Universitas Diponegoro in Semarang, and Gatot Soebroto RSPAD Hospital in Jakarta. Vaknus can be used for all ages, starting from children under 17 years old to people above 60 years old. It is also safe for people who have comorbid.

Earlier, to ensure the development of the second phase clinical test of the newest COVID-19 vaccine named Nusantara Vaccine, Commission IX of the Indonesian House of Representatives visited Dokter Kariadi General Hospital in Semarang. 

The vaccine, made by Indonesians, can be used in one injection, and can be used for everyone without exception. These include the elderly, people with comorbid, people with hypertension, as well people with autoimmune issues.

Commission IX's visit to Dokter Kariadi General Hospital was led by Emanuel Melkiades Laka Lena, Deputy Leader of Commission IX.